Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01330173 · ClinicalTrials.gov registry record · Phase 1
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
A Phase 1 study of Refractory Plasma Cell Myeloma and DS Stage I Plasma Cell Myeloma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT01330173 is a Phase 1 study of Refractory Plasma Cell Myeloma and DS Stage I Plasma Cell Myeloma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, above the 45-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (11% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT01330173, a Phase 1 study of Refractory Plasma Cell Myeloma and DS Stage I Plasma Cell Myeloma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies how well vismodegib after stem cell transplant works in treating patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the growth of cancer cells. Giving vismodegib after autologous stem cell transplant may kill more multiple myeloma cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Vismodegib
- OTHER Pharmacological Study
Study Locations (2)
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01330173
The ClinicalTrials.gov registry entry for NCT01330173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (11% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01330173 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01330173 about?
NCT01330173 is a clinical study titled "Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma". This phase I trial studies how well vismodegib after stem cell transplant works in treating patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the growth of cancer cells. Giving vismodegib after autologous stem cell transplant may kill more multiple myeloma cel...
What is the current status of trial NCT01330173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-12. Estimated completion is 2014-11.
What conditions does trial NCT01330173 study?
This clinical trial studies the following conditions: Refractory Plasma Cell Myeloma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma.
What interventions are being tested in trial NCT01330173?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Vismodegib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01330173?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01330173 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
RECRUITING · Phase 1
-
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Refractory Plasma Cell Myeloma
All registered trials for this condition
DS Stage I Plasma Cell Myeloma
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.